Onesource Specialty Pharma (ONESOURCE) Fundamentals 2026 — Revenue Analysis | SniperIQ
Onesource Specialty Pharma (ONESOURCE) is a India-listed Healthcare company in Biotechnology with a market capitalization of ₹19,163 Crore, trading at ₹1671.50 on the NSE. This SniperIQ fundamentals page covers Onesource Specialty Pharma's valuation, profitability (net margin -5.2%), revenue (₹1,422 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Onesource Specialty Pharma's market cap?
Onesource Specialty Pharma (ONESOURCE) has a market capitalization of approximately ₹19,163 Crore, trading at ₹1671.50 on the NSE. Market cap moves with the live share price.
What is Onesource Specialty Pharma's P/E ratio?
Onesource Specialty Pharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Onesource Specialty Pharma?
Onesource Specialty Pharma runs a net profit margin of -5.2%, a gross margin of 49.7%, and an operating margin of 1.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Onesource Specialty Pharma generate?
Onesource Specialty Pharma reported revenue of ₹1,422 Crore for fiscal year 2025, with net income of -₹74 Crore and earnings per share (EPS) of -6.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Onesource Specialty Pharma pay a dividend?
Onesource Specialty Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Onesource Specialty Pharma financially healthy?
Onesource Specialty Pharma carries a debt-to-equity ratio of 0.26x and a current ratio of 0.99x, with a market beta of 1.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Onesource Specialty Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Onesource Specialty Pharma (ONESOURCE) the key facts are: market cap ₹19,163 Crore, revenue ₹1,422 Crore, 52-week range 1057-2026.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Onesource Specialty Pharma's full fundamentals live
Get Onesource Specialty Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.